Covid jab maker BioNTech said Monday it would build a Southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of mRNA-based vaccines per year. Construction of the site will start this year, and it could become operational by 2023, the German company said in a statement.…

This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.